© Reuters. FILE PHOTO: Bottles of prescription painkillers Oxycodone Hydrochloride, 30mg tablets, made by Mallinckrodt sit on a counter at an area pharmacy, in Provo, Utah, U.S., April 25, 2017. REUTERS/George Frey/File Photo
(Reuters) – Bankrupt drugmaker Mallinckrodt (OTC:) is in talks with main traders about promoting some or all of its business models, which might result in its exit from the opioid business, the Wall Street Journal reported on Monday, citing individuals conversant in the discussions.
Some traders, poised to take management by the corporate’s ongoing chapter proceedings, are suggesting Mallinckrodt break up its business models, the report mentioned.
Mallinckrodt didn’t instantly reply to a Reuters request for remark.
The Ireland-based firm filed for its second chapter within the United States final month, with a restructuring plan that may lower $1 billion from what it owes to victims of the U.S. opioid disaster.
Mallinckrodt, which makes each branded and generic medicine, had first filed for chapter in 2020 to deal with its excessive debt load, litigation over its advertising and marketing of extremely addictive generic opioids and disputes over its drug pricing.
As half of its plan to emerge from chapter in June 2022, the corporate, which denied wrongdoing, agreed to pay $1.7 billion to settle about 3,000 lawsuits alleging it used misleading advertising and marketing ways to spice up opioid gross sales.
Mallinckrodt additionally disclosed in filings with the Securities and Exchange Commission final month that it just lately acquired a grand jury subpoena from the U.S. Attorney’s Office for the Western District of Virginia, in search of details about its reporting of suspicious opioid orders to the U.S. Drug Enforcement Administration.